Keywords: Peregrine Pharma, Bavituximab, NSCLC, Ph IIb
Peregrine leaps 56% as bavituximab shown to double NSCLC patient survival
Article | 10 September 2012
Shares of US biotech firm Peregrine Pharmaceuticals (Nasdaq: PPHM) rocketed 56.4% to $4.80 last Friday, after the company presented positive interim results ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
